PROK underperforms with a -8.27 decrease in share price

While ProKidney Corp has underperformed by -8.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PROK rose by 37.87%, with highs and lows ranging from $7.13 to $0.46, whereas the simple moving average jumped by 50.92% in the last 200 days.

On June 30, 2025, BofA Securities Downgraded ProKidney Corp (NASDAQ: PROK) to Underperform. A report published by JP Morgan on September 30, 2024, Initiated its previous ‘Neutral’ rating for PROK. Guggenheim also rated PROK shares as ‘Buy’, setting a target price of $6 on the company’s shares in an initiating report dated September 10, 2024. Morgan Stanley Initiated an Equal-Weight rating on March 07, 2024, and assigned a price target of $3. BofA Securities January 02, 2024d its ‘Buy’ rating to ‘Neutral’ for PROK, as published in its report on January 02, 2024. BTIG Research’s report from July 25, 2023 suggests a price prediction of $16 for PROK shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.

Analysis of ProKidney Corp (PROK)

One of the most important indicators of ProKidney Corp’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 11.48, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

For any stock, average volume can also provide valuable insight into volatility, and PROK is recording 13.27M average volume. On a monthly basis, the volatility of the stock is set at 12.94%, whereas on a weekly basis, it is put at 10.72%, with a gain of 4.02% over the past seven days. Furthermore, long-term investors anticipate a median target price of $5.83, showing growth from the present price of $2.33, which can serve as yet another indication of whether PROK is worth investing in or should be passed over.

How Do You Analyze ProKidney Corp Shares?

Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 26.41%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.46% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

Hot this week

ACHV’s price-to-cash ratio: Is it a good investment at the moment?

Achieve Life Sciences Inc (ACHV)'s stock has witnessed a...

Examining ELAB’s book value per share for the latest quarter

Currently, PMGC Holdings Inc's (ELAB) stock is trading at...

EEIQ’s price-to-free cash flow ratio: What it means for investors

In the current trading session, EpicQuest Education Group International...

Should investors be concerned about CTXR’s high price-to-sales ratio?

Citius Pharmaceuticals Inc (CTXR)'s stock is trading at $1.36...

TCRT’s valuation metrics: A comprehensive analysis

Alaunos Therapeutics Inc (TCRT)'s stock has witnessed a price...

Topics

ACHV’s price-to-cash ratio: Is it a good investment at the moment?

Achieve Life Sciences Inc (ACHV)'s stock has witnessed a...

Examining ELAB’s book value per share for the latest quarter

Currently, PMGC Holdings Inc's (ELAB) stock is trading at...

EEIQ’s price-to-free cash flow ratio: What it means for investors

In the current trading session, EpicQuest Education Group International...

Should investors be concerned about CTXR’s high price-to-sales ratio?

Citius Pharmaceuticals Inc (CTXR)'s stock is trading at $1.36...

TCRT’s valuation metrics: A comprehensive analysis

Alaunos Therapeutics Inc (TCRT)'s stock has witnessed a price...

How does PTIX’s price to cash per share ratio compare in the market?

Currently, Protagenic Therapeutics Inc's (PTIX) stock is trading at...

Analyzing MODV’s price-to-book ratio for the last quarter

In the current trading session, ModivCare Inc's (MODV) stock...

A closer look at APM’s price-to-free cash flow ratio

Aptorum Group Ltd (APM)'s stock is trading at $2.55...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.